{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:03:21Z","timestamp":1775621001817,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejogrb.2023.05.031","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T01:56:38Z","timestamp":1685152598000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis"],"prefix":"10.1016","volume":"287","author":[{"given":"Fangxiang","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejogrb.2023.05.031_b0005","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3390\/cells11121923","article-title":"Stem cell-based trophoblast models to unravel the genetic causes of human miscarriages","volume":"11","author":"Nikitina","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.05.031_b0010","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/jpm12050775","article-title":"The role of endometrial stem\/progenitor cells in recurrent reproductive failure","volume":"12","author":"Al-Lamee","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0015","doi-asserted-by":"crossref","unstructured":"RPL EGGo, Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018;2018:hoy004.","DOI":"10.1093\/hropen\/hoy004"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41572-020-00228-z","article-title":"Recurrent pregnancy loss","volume":"6","author":"Dimitriadis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-2000-13722","article-title":"The epidemiology of recurrent pregnancy loss","volume":"18","author":"Cramer","year":"2000","journal-title":"Semin Reprod Med"},{"issue":"01","key":"10.1016\/j.ejogrb.2023.05.031_b0030","doi-asserted-by":"crossref","first-page":"054","DOI":"10.1055\/a-1717-7663","article-title":"Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom?","volume":"42","author":"Middeldorp","year":"2022","journal-title":"Hamostaseologie"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.05.031_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.semperi.2018.12.004","article-title":"Endocrine causes of recurrent pregnancy loss","volume":"43","author":"Amrane","year":"2019","journal-title":"Semin Perinatol"},{"issue":"10285","key":"10.1016\/j.ejogrb.2023.05.031_b0040","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(21)00682-6","article-title":"Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss","volume":"397","author":"Quenby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejogrb.2022.06.001","article-title":"Genomic instability and the link to infertility: A focus on microsatellites and genomic instability syndromes","volume":"274","author":"Wieland","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.05.031_b0050","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.05.031_b0055","doi-asserted-by":"crossref","first-page":"103101","DOI":"10.1016\/j.autrev.2022.103101","article-title":"Antiphospholipid antibodies in women with recurrent embryo implantation failure: A systematic review and meta-analysis","volume":"21","author":"Jarne-Borr\u00e0s","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0060","doi-asserted-by":"crossref","unstructured":"Alijotas-Reig J, Esteve-Valverde E, Anunciacion-Llunell A, Marques-Soares J, Pardos-Gea J, Miro-Mur F. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11030675"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/GCO.0000000000000735","article-title":"Management of recurrent miscarriages: an overview of current evidence","volume":"33","author":"Tsonis","year":"2021","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0070","first-page":"e10956","article-title":"Role of low molecular weight heparin in the management of unexplained recurrent pregnancy loss: A review of literature","volume":"12","author":"Awolumate","year":"2020","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.ejogrb.2023.05.031_b0075","doi-asserted-by":"crossref","first-page":"e012184","DOI":"10.1161\/JAHA.119.012184","article-title":"Fondaparinux sodium compared with low-molecular-weight heparins for perioperative surgical thromboprophylaxis: A systematic review and meta-analysis","volume":"8","author":"Kumar","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.05.031_b0080","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s11695-021-05825-9","article-title":"Efficacy and safety of pharmacoprophylaxis for venous thromboembolism in patients undergoing bariatric surgery: a systematic review and meta-analysis","volume":"32","author":"Zhao","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0085","doi-asserted-by":"crossref","unstructured":"Hamulyak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020;5:CD012852.","DOI":"10.1002\/14651858.CD012852.pub2"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.717630","article-title":"Retrospective analysis of fondaparinux and low-molecular-weight heparin in the treatment of women with recurrent spontaneous abortion","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0897.2009.00733.x","article-title":"A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss","volume":"62","author":"Winger","year":"2009","journal-title":"Am J Reprod Immunol"},{"issue":"Suppl","key":"10.1016\/j.ejogrb.2023.05.031_b0100","first-page":"2","article-title":"Fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss","volume":"95","author":"Winger","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0105","first-page":"5","article-title":"Comparison between enoxaparin and fondaparinux sodium on anticoagulant therapy in pregnant patient with recurrent miscarriage","volume":"26","author":"Guo","year":"2020","journal-title":"Contemporary Med"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0110","first-page":"106","article-title":"Effect of enoxaparin and fondaparinux in anticoagulant therapy for re-pregnant women with recurrent miscarriage","volume":"48","author":"Liu","year":"2021","journal-title":"Chin J Pract Med"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0115","first-page":"55","article-title":"Comparison of curative effect of fondaparinux sodium and low molecular weight heparin on recurrent spontaneous abortion","volume":"60","author":"Yang","year":"2022","journal-title":"China Modern Doctor"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0120","unstructured":"Wells GA, Shea B, O\u2019Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.ejogrb.2023.05.031_b0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-8-22","article-title":"Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies","volume":"8","author":"Lundh","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"S1","key":"10.1016\/j.ejogrb.2023.05.031_b0135","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.5045\/br.2022.2022068","article-title":"Diagnosis and management of thrombocytopenia in pregnancy","volume":"57","author":"Park","year":"2022","journal-title":"Blood Res"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.05.031_b0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.mcna.2020.10.002","article-title":"Pregnancy and management in women with rheumatoid arthritis, systemic lupus erythematosus, and obstetric antiphospholipid syndrome","volume":"105","author":"Castro-Gutierrez","year":"2021","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.05.031_b0145","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.05.031_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0961203312465782","article-title":"Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management","volume":"22","author":"Alijotas-Reig","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0155","doi-asserted-by":"crossref","unstructured":"Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;1:CD006649.","DOI":"10.1002\/14651858.CD006650.pub5"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0160","article-title":"Maternal low volume circulation relates to normotensive and preeclamptic fetal growth restriction","volume":"9","author":"Gyselaers","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/4308470","article-title":"Antiphospholipid antibodies increase the risk of fetal growth restriction: a systematic meta-analysis","volume":"2022","author":"Xu","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.05.031_b0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ogc.2021.03.002","article-title":"Recurrence risk of fetal growth restriction: management of subsequent pregnancies","volume":"48","author":"Blue","year":"2021","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.05.031_b0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s11739-020-02609-4","article-title":"Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis","volume":"16","author":"Urban","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejogrb.2023.05.031_b0180","doi-asserted-by":"crossref","unstructured":"Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, Zanetto A, et al. Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. Am J Med. 2021;134:1278-85 e2.","DOI":"10.1016\/j.amjmed.2021.05.013"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152300221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152300221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:00:16Z","timestamp":1759557616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121152300221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":36,"alternative-id":["S030121152300221X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.05.031","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}